Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

Dermatology

Volumn 211, Issue 2, 2005, Pages 174-187

  Hultsch, Thomas ^a   Kapp, Alexander ^b   Spergel, Jonathan ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Immunosuppression; Lymphoproliferative disease; Th1 Th2 balance; Topical corticosteroids

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; PLACEBO; TACROLIMUS;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; ALLERGIC DISEASE; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CARCINOGENICITY; CHILDHOOD DISEASE; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; CREAM; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; ENDOCRINE DISEASE; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FOLLOW UP; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIPOPHILICITY; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MONKEY; NONHUMAN; OINTMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT COURSE THERAPY; SIDE EFFECT; SKIN ABSORPTION; SKIN ATROPHY; SKIN TOXICITY; STRIA; SYSTEMIC DISEASE; TELANGIECTASIA; TH2 CELL; TOPICAL TREATMENT; UNITED STATES;

ADMINISTRATION, TOPICAL; ANIMALS; CALCINEURIN; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RATS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 23844476199     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086739     Document Type: Article

References (103)

1. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG: The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994;30:35-39.
2. Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112(6suppl):S118-S127.
3. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis. J Clin Invest 2004;113:651-657.
4. Williams HC, Strachan DP: The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 1998;139:834-839.
5. Wuthrich B: Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol 1999;83:464-470.
6. Paller AS, McAlister RO, Doyle JJ, Jackson A: Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 2002;41:323-332.
7. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, Sampson HA, Lupo M: Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995;149:856-860.
8. Bender BG, Leung SB, Leung DY: Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol 2003;111:598-602.
9. Breuer K, Werfel T, Kapp A: Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005;6:65-77.
10. Bergmann RL, Edenharter G, Bergmann KE, Forster J, Bauer CP, Wahn V, Zepp F, Wahn U: Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998;28:965-970.
11. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD: A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000;162:1403-1406.
12. Gustafsson D, Sjoberg O, Foucard T: Development of allergies and asthma in infants and young children with atopic dermatitis - a prospective follow-up to 7 years of age. Allergy 2000;55:240-245.
13. Cookson W: The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004;4:979-988.
14. Hamid Q, Boguniewicz M, Leung DY: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94:870-876.
15. Novak N, Bieber T, Leung DY: Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112(6 suppl):S128-S139.
16. Rowe J, Macaubas C, Monger TM, Holt BJ, Harvey J, Poolman JT, Sly PD, Holt PG: Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect Immun 2000;68:3873-3877.
17. Miyawaki T, Seki H, Taga K, Sato H, Taniguchi N: Dissociated production of interleukin-2 and immune (gamma) interferon by phytohaemagglutinin stimulated lymphocytes in healthy infants. Clin Exp Immunol 1985;59:505-511.
18. Sorg RV, Kogler G, Wernet P: Identification of cord blood dendritic cells as an immature CD11c- population. Blood 1999;93:2302-2307.
19. Hunt DW, Huppertz HI, Jiang HJ, Petty RE: Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood 1994;84:4333-4343.
20. Dewar AL, Doherty KV, Woods GM, Lyons AB, Muller HK: Acquisition of immune function during the development of the Langerhans cell network in neonatal mice. Immunology 2001;103:61-69.
21. Wollenberg A, Kraft S, Hanau D, Bieber T: Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446-453.
22. Sulzberger MB, Witten VH, Smith CC: Hydrocortisone (compound F) acetate ointment in dermatological therapy. J Am Med Assoc 1953;151:468-472.
23. Leung DY, Bloom JW: Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003;111:3-22.
24. Kalthoff FS, Chung J, Musser P, Stuetz A: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003;133:350-359.
25. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Bürger A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005;115:1276-1283.
26. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004;122:673-684.
27. Aberer W, Romani N, Elbe A, Stingl G: Effects of physicochemical agents on murine epidermal Langerhans cells and Thy-1-positive dendritic epidermal cells. J Immunol 1986;136:1210-1216.
28. Shapiro R: Tacrolimus in pediatric renal transplantation: a review. Pediatr Transplant 1998;2:270-276.
29. Tanner JE, Alfieri C: The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001;3:60-69.
30. Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski GJ: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52:810-822.
31. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM: A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-644.
32. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
33. Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R: 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004;150:554-562.
34. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-821.
35. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-277.
36. Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY: Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004;114:691-693.
37. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
38. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin ME, Burtin P, Stephenson TJ: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-973.
39. Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004;15:169-178.
40. Papp KA, Werfel T, Folster-Holst R, Ortonne JP, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C: Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005;52:240-246.
41. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365-372.
42. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, Stiller M, Tschen E, Chon K, Wisseh S, Abrams B: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004;51:515-525.
43. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
44. Breuer K, Braeutigam M, Kapp A, Werfel T: Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004;209:314-320.
45. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-273.
46. Bornhovd EC, Burgdorf WH, Wollenberg A: Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs 2002;3:708-712.
47. Kalthoff FS, Chung J, Stuetz A: Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 2002;130:85-92.
48. Winiski AP, Kalthoff F, Fichtinger P, Olt S, Schwendinger B, Weishaeupl C, Stuetz A: Human T cells are differentially susceptible to pimecrolimus and tacrolimus depending on their history of stimulation (abstract). J Invest Dermatol 2005;124:A45.
49. Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Burger A, Stutz A: Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003;149:853-857.
50. Kuipers H, Heirman C, Hijdra D, Muskens F, Willart M, van Meirvenne S, Thielmans K, Hoogsteden HC, Lambrecht BN: Dendritic cells retrovirally overexpressing IL-12 induce strong Th1 responses to inhaled antigen in the lung but fail to revert established Th2 sensitization. J Leukoc Biol 2004;76:1028-1038.
51. Mainali ES, Kikuchi T, Tew JG: Dexamethasone inhibits maturation and alters function of monocyte-derived dendritic cells from cord blood. Pediatr Res 2005, March 17: E-pub ahead of print.
52. Turpeinen M, Salo OP, Leisti S: Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-484.
53. Aalto-Korte K, Tuipeinen M: Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br J Dermatol 1995;133:259-263.
54. Cutivate Cream 0.05% (prescribing information): Pittsburgh, Glaxosmithkline, 2002.
55. Friedlander SF, Hebert AA, Allen DB: Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-393.
56. Clobex lotion 0.05% (prescribing information). Fort Worth, Galderma Laboratories, 2004.
57. Department of Health and Human Services, FDA, CDER: Joint session with the nonprescription and dermatologic drugs advisory committee, vol 2. FDA 2, 1-330, 2004. http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4099T1.htm.
58. Billich A, Aschauer H, Aszodi A, Stuetz A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35.
59. Billich A, Aschauer H, Stuetz A: In vitro penetration/permeation of pimecrolimus and tacrolimus from their marketed formulations (Elidel and Protopic) (abstract). J Invest Dermatol 2004;122:A40.
60. Hultsch T: Elidel (pimecrolimus) cream 1% safety update February 2005. Internet, CS-10. 2005. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4089s2_02_02_Novartis% 20Core%20Safety%20(CS).pdf.
61. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-787.
62. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R: Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003;207:37-42.
63. Van Leent EJM, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated topical application of pimecrolimus (Elide®, SDZASM981) in patients with atopic dermatitis. Dermatology 2002;204:63-68.
64. Elidel (prescribing information). East Hanover, Novartis Pharmaceuticals, 2004.
65. Drug Regulatory Affairs: Elidel (pimecrolimus) cream 1%. NDA 21-302, 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm.
66. Hill B: Topical immunosuppressants (calcineurin inhibitors) - animal toxicology. http://www.fda.gov/ohrms/dockets/ac/05/slides/2005- 4089s2_01_06_Hill.ppt.
67. Protopic (package insert). Deerfield, Fujisawa, 2000.
68. Halper J, Smith C, Rubins A, Green A, Jackson K, Zigure S, Bourke J, Alomar A, Stevenson P, Foster C, Undre N: A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005;124:695-699.
69. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, Korman NJ: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001;137:747-750.
70. Oji V, Beljan G, Beier K, Traupe H, Luger T: Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Abstract Eur Acad Dermatol Venereol 13th Congr, Florence, Italy, Nov 17-21, 2004.
71. Stuetz A, Grassberger M, Meingassner JG: Pimecrolimus (Elidel, SDZ ASM 981) -pre-clinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-241.
72. Meingassner J, Hiestand P, Bigout M, Grassberger M, Schuurman H, Tanner M, Stuetz A: SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506 (abstract). J Invest Dermatol 2001;117:532.
73. Meingassner JG, Di Padova F, Hiestand P, Bigaud P, Grassberger M, Schuurman H, Tanner M, Stuetz A: Pimecrolimus (Elidel®, SDZ ASM 981): highly effective in models of skin inflammation but low activity in models of immunosuppression (abstract). J Eur Acad Dermatol Venereol 2001;15:214.
74. Meingassner JG, Fahrngruber H, Bavandi A: Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003;121:77-80.
75. Food and Drug Administration: Pharmacokinetics/toxicokinetics. Brief summary. 2005:1-18. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2_01_07_ Tox%20Review%20Redacted.pdf.
76. Wijnen RM, Ericzon BG, Tiebosch AT, Buurman WA, Groth CG, Kootstra G: Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int 1992;5(suppl 1):S454-S458.
77. Food and Drug Administration: Protopic (tacrolimus) ointment. Center for Drug Evaluation and Research Application Number NDA 50777. 2005:1-51. http://www.fda.gov/cder/foi/nda/2000/50777_protopic.htm.
78. Food and Drug Administration, Pediatric Advisory Committee: Discussion topic: risk evaluation, labeling, risk communication, and dissemination of information on potential cancer risk among pediatric patients treated for atopic dermatitis with topical dermatological immunosuppressants. 2005:1-30. http://www. fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2_02_02_Protopic%20Fujisawa%20briefing.pdf.
79. Wellington K, Noble S: Pimecrolimus: a review of its use in atopic dermatitis. Am J Clin Dermatol 2004;5:479-495.
80. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:805-809.
81. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K, Van Der Valk PG, Bos JD: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-794.
82. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, Folster-Holst R, Potter P, Marshall K, Thurston M, Bush C, Cherill R: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155-162.
83. 3 Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-284.
84. Boguniewicz M, Eichenfield LF, Hultsch T: Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003;112(6 suppl):S140-S150.
85. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005;52:247-253.
86. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ: Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol, in press.
87. Food and Drug Administration: ODS post-marketing safety review (PID 040609). Pimecrolimus (Elidel, NDA 21-302). 2004: 1-12. http://www.fda.gov/ ohrms/dockets/ac/05/briefing/2005-4089b2_01_04_Pimecrol imus%20IMS%20Cleared%20AE%20LT%20 2%20YO%20Malignancy.pdf.
88. Food and Drug Administration: ODS post-marketing safety review (PID 040608). Tacrolimus, topical (Protopic, NDA 50-777). 2004: 1-16. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2_01_03_Tacrolimus%20Topical%20IMS%20Cleared%20LT%2 02%20and%20Malignancy%20Update.pdf.
89. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P: Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol 1987;7:294-299.
90. Knowles DM: Immunodeficiency-associated lymphoprohferative disorders. Mod Pathol 1999;12:200-217.
91. Levine AM: Lymphoma complicating immunodeficiency disorders. Ann Oncol 1994;5(suppl2):29-35.
92. Kinlen LJ: Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-49.
93. Stiehm ER: Conventional therapy of immunodeficiency diseases; in Ochs HD, Smith CIE, Puck JM (eds): Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, Oxford University Press, 1999, pp 448-458.
94. Faye A, Vilmer E: Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs 2005;7:55-65.
95. Swinnen LJ: Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies. J Natl Cancer Inst Monogr 2000;28:38-43.
96. Opelz G, Dohler B: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
97. Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S, Ruutu T, Hedman K: High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003;32:97-102.
98. Bonnefoy-Berard N, Vincent C, Verrier B, Revillard JP: Monocyte-independent T-cell activation by polyclonal antithymocyte globulins. Cell Immunol 1992;143:272-283.
99. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ: Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208-2216.
100. Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 2004;127:429-432.
101. Tsai DE, Aqui NA, Vogl DT, Bloom RD, Schuster SJ, Nasta SD, Wasik MA: Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. Am J Transplant 2005;5:2070-2073.
102. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van't Veer-Korthof E, Gluckman E: Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993;329:1152-1157.
103. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A: Late clonal diseases of treated aplastic anemia. Semin Hematol 2000;37:91-101.